August 13, 2020 07:30 AM EDTUpdated 07:48 AM
Deals
China
Cell/Gene Tx

No­var­tis’ CAR-T part­ner in Chi­na wraps $383M take-pri­vate deal en­gi­neered by CEO

Amber Tong

Af­ter 13 years on Nas­daq, Cel­lu­lar Bio­med­i­cine Group is re­turn­ing to pri­vate hands.

CEO Tony (Bizuo) Liu is a key ad­vo­cate of the deal, lead­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

VP, Clinical Development / CMO / CDO‬ ‭ (Stealth Portfolio Company)

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TRENDING NOW

Lil­ly shuf­fles key ex­ec­u­tive po­si­tions; Mikael Dol­sten takes an­oth­er post-Pfiz­er as­sign­ment

Io­vance stock plum­mets af­ter low­ered full-year guid­ance, missed an­a­lyst ex­pec­ta­tions for Am­tagvi

Rev­o­lu­tion’s KRAS drugs ap­pear com­pet­i­tive in sev­er­al lung can­cer set­tings

Chron­ic care start­up Oma­da Health files to go pub­lic

Corvus' ear­ly-phase atopic der­mati­tis da­ta prompt stock ral­ly

sponsored

In one of the riski­est in­dus­tries — Biotech — a sure­fire way to neu­tral­ize some of that risk emerges

A service from the Financial Times